In the past two weeks, Goodwin’s Life Sciences team advised CRISPR Therapeutics on its strategic collaboration with ViaCyte, a privately-held regenerative medicine company, and on the completion of its approximately $200 million follow-on offering.
CRISPR Therapeutics will be collaborating with ViaCyte to discover, develop, and commercialize gene-edited allogeneic stem cell therapies for the treatment of diabetes. The combination of ViaCyte’s stem cell capabilities and CRISPR’s gene editing capabilities has the potential to enable a beta-cell replacement product that may deliver durable benefit to patients without triggering an immune reaction.
Most recently, CRISPR closed its follow-on offering of 4,210,526 common shares at a public offering price of $47.50 per share. The gross proceeds were approximately $200 million, before deducting the underwriter discounts and commissions and other offering expenses.
The Goodwin team was led by partner Robert Puopolo and included partners Mitchell Bloom, Seo Salimi, Brian Fairchild and Daniel Karelitz; counsel Stephanie Philbin; and associates Sarah Smith, Carly Ward and Alex Plaum. For additional details, please read the press release.
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.